Dr. Vickie A Turnbough, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 711 Cook Dr, Suite 110, Athens, TN 37303 Phone: 423-746-0122 Fax: 423-745-9456 |
Rebekah Danielle Sherlin-chaplin, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 325 County Road 126, Athens, TN 37303 Phone: 901-692-8880 |
Dr. Charles Richard Sharpe, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1031 W Madison Ave, Athens, TN 37303 Phone: 423-745-6575 |
Dr. Christopher L Maynard, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1031 W Madison Ave, Athens, TN 37303 Phone: 423-745-6575 |
Frederick James Barry, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1031 W Madison Ave, Athens, TN 37303 Phone: 865-373-7100 Fax: 865-373-7101 |
Dr. Jeffrey Joseph Ivins, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 711 Cook Dr, Suite 110, Athens, TN 37303 Phone: 423-746-0122 Fax: 423-745-9456 |
News Archive
As the prevalence of overweight and obesity increases among American children, signs of risk for chronic diseases such as type 2 diabetes and cardiovascular diseases - previously thought of as adult disorders - are on the rise among youth.
The U.S. Food and Drug Administration (FDA) has approved the marketing of the first laboratory test system that will allow physicians to consider unique genetic information from patients in selecting medications and doses of medications for a wide variety of common conditions such as cardiac disease, psychiatric disease, and cancer.
In adult skeletal muscle, loss of myofiber integrity caused by mechanical injuries or diseases are repaired by resident muscle stem cells, called satellite cells, which promptly exit from quiescence after disruption of muscle architecture to expand, differentiate and drive tissue regeneration.
Merck's HPV vaccine Gardasil and GlaxoSmithKline's HPV vaccine Cervarix in clinical trials have been shown to be 100% effective in preventing infection with HPV strains 16 and 18, which together cause about 70% of cervical cancer cases.
Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.
› Verified 4 days ago